Serum protocadherin 18 as a potential biomarker for antiphospholipid syndrome: a case-control study
Rheumatology International · 2026
DOI: 10.1007/s00296-026-06284-0 ↗Kurz gefasst
Fall-Kontroll-Studie in der Zeitschrift Rheumatology International, 2026. Verfasst von Yuebing Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People's Hospital,…. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, Cadherins. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Shandong Provincial Natural Science Foundation, Beijing Natural Science Foundation, Peking University People's Hospital Research And Development Fund.
Abstract (Originalsprache)
This study aimed to evaluate the discriminatory capacity of serum Protocadherin 18 (PCDH18) for Antiphospholipid Syndrome (APS), investigate its association with specific clinical and laboratory manifestations. A total of 208 participants were enrolled, including 104 patients with APS, 28 asymptomatic aPL carriers, and 76 healthy donors (HD). Serum PCDH18 levels were quantified using enzyme-linked immunosorbent assay (ELISA). We evaluated the associations of PCDH18 levels with clinical manifestations and laboratory test parameters. The discriminatory capacity was evaluated using Receiver Operating Characteristic (ROC) curve analysis. Serum PCDH18 levels were significantly elevated in APS patients compared to both aPL carriers and HD [97.42 (IQR: 82.48) pg/mL vs. 42.74 (IQR: 52.95) pg/mL, P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People's Hospital, Beijing, China.
- Clinical Laboratory Diagnostic Center, People's Hospital of Ningxia Hui Autonomous Region, Yinchuang, Ningxia, China.
- Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People's Hospital, Beijing, China. doctorliru123@163.com.
- Department of Rheumatology and Immunology, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, China. doctorliru123@163.com.
- Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People's Hospital, Beijing, China. 13811190098@163.com.
- Department of Rheumatology and Immunology, Peking University People's Hospital, Qingdao, Shandong, China. 13811190098@163.com.
Förderung
- Shandong Provincial Natural Science Foundation
- Beijing Natural Science Foundation
- Peking University People's Hospital Research And Development Fund
Zitieren
APA
Wang, Y., Guo, G., Liu, X., Chen, X., Chang, Y., Liu, L., Li, R., & Li, C. (2026). Serum protocadherin 18 as a potential biomarker for antiphospholipid syndrome: a case-control study. Rheumatology International. https://doi.org/10.1007/s00296-026-06284-0
Vancouver
Wang Y, Guo G, Liu X, Chen X, Chang Y, Liu L, et al. Serum protocadherin 18 as a potential biomarker for antiphospholipid syndrome: a case-control study. Rheumatology International. 2026. doi:10.1007/s00296-026-06284-0
BibTeX
@article{Wang2026,
author = {Wang, Yuebing and Guo, Guijuan and Liu, Xiangjun and Chen, Xiaoyu and Chang, Yuhan and Liu, Lianzeran and Li, Ru and Li, Chun},
title = {Serum protocadherin 18 as a potential biomarker for antiphospholipid syndrome: a case-control study},
journal = {Rheumatology International},
year = {2026},
doi = {10.1007/s00296-026-06284-0}
}
EUVIMED